Trials in Miami, Florida
Here are the top 10 medical studies for alzheimer's disease in Miami, Florida
Popular Filters
Phase 3 Trials
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Doral, Florida
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Doral, Florida
This trial is testing whether semaglutide has a positive effect on early Alzheimer's disease by comparing it to a placebo. There will be 17 clinic visits and 1 phone call with the study doctor, and various tests and scans will be performed. The study will last for up to 173 weeks.
Monoclonal Antibodies
Donanemab for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Miami, Florida
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Trials With No Placebo
Behavioural Intervention
Sleep and Exercise for Alzheimer's Disease
Recruiting1 award4 criteria
Miami, Florida
This trial is studying whether better sleep and more exercise can reduce the risk of dementia in people who are at risk. The idea is that these lifestyle changes might help keep the brain healthy.
Behavioural Intervention
Health Information Technology for Dementia Care
Recruiting1 award10 criteria
Miami, Florida
This trial will develop and design a personalized AAC device that relies on information technology (IT) and touchscreens to promote communication and personhood for PWD about their care preferences and experiences.
Small Molecule
Simufilam for Alzheimer's Disease
Recruiting1 awardPhase 2
Palmetto Bay, Florida
This trial involves patients with mild-to-moderate Alzheimer's disease taking simufilam regularly. It aims to see if the medication is safe and effective over time. Simufilam works by targeting proteins in the brain that are associated with Alzheimer's.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.